Article
Switching to Daily Doravirine/Islatravir (100/0.25 mg) Maintains Viral Suppression Through Week 48 Despite Baseline Non-Nucleoside Reverse Transcriptase Inhibitor Resistance-Associated Mutations or M184I/V in Proviral DNA.
The Journal of infectious diseases - 23 Sept 2026
Diamond Tracy L, Grandhi Anjana, Fuszard Monica, Xu Yayun, Nwoke Uchechukwu, Zhang Ying, Klopfer Stephanie O, Eves Karen, Benner Jaime, Li Mengchun, Greaves Wayne, Lahoulou Rima, Kim Jason, Fox Michelle C, Asante-Appiah Ernest
Abstract excerpt
BACKGROUND: Doravirine/islatravir (DOR/ISL) is a 2-drug, single-tablet regimen in clinical development for once-daily treatment of adults living with HIV-1. We examined the impact of baseline resistance-associated mutations (RAMs) in proviral DNA on the response to DOR/ISL (100/0.25 mg) in virologically suppressed participants in three phase 3 studies. METHODS: Samples were collected pre-dose from participants in...
Read the complete abstract on PubMedTopics
- Adult
- Female
- Humans
- Male
- Middle Aged